Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 491-496

  Ueda, Akira ^a   Hosokawa, Ayumu ^a   Ogawa, Kohei ^a   Yoshita, Hiroki ^a   Ando, Takayuki ^a   Kajiura, Shinya ^a   Fujinami, Haruka ^a   Jun, Kengo Kawai ^a   Kazuto, Nishikawa ^a   Minemura, Tajiri Masami ^a   Sugiyama, Toshiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Clinical practice; Gemcitabine; S 1

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; JAUNDICE; LEUKOPENIA; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PHYSICAL PERFORMANCE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SYNCHRONOUS MALIGNANCY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 84877895297     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S43287     Document Type: Article

References (15)

1. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. Jpn J Clin Oncol. 2008; 38(9):641-648.
2. Tsukuma H, Ajiki W, Ioka A, Oshima A. Survival of cancer patients diagnosed between 1993 and 1996: a collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol. 2006;36(9):602-607.
3. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical beneft with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcit-abine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19): 1817-1825.
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966.
6. Ioka T, Ikeda M, Ohkawa S, et al. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol. 2011;29:abstr 4007.
7. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncolog y. 2000;59(4):296-301.
8. Tanaka T, Ikeda M, Okusaka T, et al. Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol. 2008;38(11): 755-761.
9. Sawaki A, Kanemitsu Y, Mizuno N, et al. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol. 2008;23(8 Pt 1):1292-1297.
10. Pine JK, Fusai KG, Young R, et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol. 2009;35(6):605-610.
11. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9(2):132-138.
12. Kim ST, Choi YJ, Park KH, et al. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benifit from second-line chemotherapy. Clin Oncol (R Coll Radiol). 2012;24(2):105-111.
13. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifes five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14): 1715-1724.
14. Baka S, Ashcroft L, Anderson H, et al. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status £ 70) and advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(10):2136-2144.
15. Leong SS, Toh CK, Lim WT, et al. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol. 2007;2(3):230-236.